Teresa A Olejnik

Learn More
PURPOSE Rituximab is commonly used as a single agent or in combination therapy for non-Hodgkin's lymphoma (NHL). Ibritumomab tiuxetan radioimmunotherapy targets the same antigen as rituximab and has demonstrated efficacy in rituximab-naïve NHL. This study evaluated ibritumomab tiuxetan in the treatment of rituximab-refractory follicular NHL. PATIENTS AND(More)
BACKGROUND CD23, a cell-surface molecule, is involved in a variety of pathways likely to influence IgE production and inflammation in allergic disorders, such as allergic rhinitis and allergic asthma. OBJECTIVE This study investigated the safety, clinical activity, and pharmacokinetic profile of IDEC-152, an IgG1 anti-CD23 antibody, in patients with(More)
The treatment of malignant lymphoma has improved over the past 20 years, but the majority of patients are not cured. New modalities using targeted therapy based on new information in molecular biology and immunology hold promise for better outcomes with less toxicity. We review data on the use of radiolabeled monoclonal antibodies directed against the CD20(More)
In 1974 an epidemic of lymphocytic cerebrospinal meningitis occurred in the Province of Bydgoszcz. Thirty-nine cases of this disease were hospitalized at the neurological department of the hospital in Grudziadz. Virological investigations demonstrated presence of Coxsackie A9 virus. The manifestations of the disease, diagnostic methods and treatment are(More)
  • 1